MeSH D008232 - lymphoproliferative disorders
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D008206:Lymphatic diseases
0 Companies
0 Drugs
Success rate
D008232:
Lymphoproliferative disorders
D000361:Agammaglobulinemia
0 Companies
0 Drugs
Success rate
D006099:Granuloma
0 Companies
0 Drugs
Success rate
D006362:Heavy chain disease
0 Companies
0 Drugs
Success rate
D007119:Immunoblastic lymphadenopathy
0 Companies
0 Drugs
Success rate
D007943:Hairy cell leukemia
D007945:Lymphoid leukemia
D008203:Lymphangiomyoma
0 Companies
0 Drugs
Success rate
D008223:Lymphoma
D008258:Waldenstrom macroglobulinemia
D008380:Marek disease
0 Companies
0 Drugs
Success rate
D012507:Sarcoidosis
D012751:Sezary syndrome
D056735:Autoimmune lymphoproliferative syndrome
0 Companies
0 Drugs
Success rate
D000075363:Immunoglobulin light-chain amyloidosis
0 Companies
0 Drugs
Success rate
D007161:Immunoproliferative small intestinal disease
0 Companies
0 Drugs
Success rate
D009101:Multiple myeloma
D010954:Plasmacytoma
0 Companies
0 Drugs
Success rate
D055501:Macrophage activation syndrome
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Bristol Myers Squibb | Idecabtagene vicleucel | Abecma | 2021-08-18 | $419 M | Q3/24-Q2/25 | |
| Laboratoires Pierre Fabre | Tabelecleucel | Ebvallo | 2022-12-16 |
Clinical Trials
Historical Success Rate
Phase 1
61%19/31
Phase 2
10%6/63
Phase 3
8%1/13
Approved: 1Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use